BioCentury
ARTICLE | Company News

Gruenenthal, Forest Laboratories deal

December 15, 2014 8:00 AM UTC

Gruenenthal and Actavis plc (NYSE:ACT, Dublin, Ireland) terminated a 2010 deal granting Actavis’ subsidiary, Forest Laboratories, exclusive rights to co-develop and commercialize cebranopadol ( GRT60...